What is the appropriate hormone replacement regimen for a patient with panhypopituitarism following surgery for a pituitary macroadenoma?

Hormone Replacement in Post-Operative Pituitary Macroadenoma with Panhypopituitarism

For panhypopituitarism following pituitary macroadenoma surgery, initiate hydrocortisone 15-20 mg daily (highest dose in morning), levothyroxine targeting free T4 in normal range, testosterone replacement in males or estrogen/progestin in premenopausal females, and consider growth hormone replacement after stabilization of other axes. 1

Critical Sequencing: Glucocorticoid FIRST

Always replace glucocorticoids before thyroid hormone to prevent precipitating adrenal crisis, as thyroid hormone increases cortisol metabolism. 1 If you cannot immediately assess adrenal function in a patient with suspected central hypothyroidism, prescribe empiric glucocorticoid therapy until definitive testing is completed. 1

Glucocorticoid Replacement

Dosing Strategy

• Hydrocortisone 15-20 mg total daily dose is the preferred agent 1
• Divide into 2-3 doses: highest dose upon awakening, second in afternoon (two-dose), or add third dose at lunch/late afternoon (three-dose) 1
• Weight-adjusted, three-times-daily dosing reduces overexposure while not perfectly replicating circadian rhythm 1
• Longer-acting glucocorticoids (prednisone, dexamethasone) are acceptable for compliance issues but hydrocortisone is preferred 1

Critical Patient Education

All patients must receive:

• Stress-dose instructions for illness/injury
• Emergency card/bracelet/necklace indicating adrenal insufficiency
• Emergency injectable glucocorticoid kit 1

Monitoring

• Avoid fludrocortisone—it is NOT indicated in secondary adrenal insufficiency 1
• Use lowest tolerable dose to minimize cardiovascular and metabolic risks 1
• Clinical assessment guides dosing; cortisol day curves have limited utility 1

Thyroid Hormone Replacement

Dosing and Monitoring

• Levothyroxine (L-T4) is the standard replacement 1
• Target free T4 levels within normal reference range 1
• Measure free T4 6-8 weeks postoperatively if preoperative thyroid function was intact 1
• Continue L-T4 if preoperative central hypothyroidism existed 1

Key Interaction

Monitor free T4 closely when starting growth hormone therapy, as GH can unmask or worsen central hypothyroidism by increasing peripheral thyroid hormone metabolism. Patients may require increased L-T4 doses. 1

Sex Hormone Replacement

Males with Central Hypogonadism

Testosterone replacement is recommended to prevent:

• Anemia
• Reduced bone mineral density
• Loss of muscle mass and strength
• Decreased libido and sexual function
• Impaired quality of life 1

Diagnose by measuring morning (before 10 AM) testosterone, FSH, LH, and prolactin after overnight fast. 1

Premenopausal Females

Estrogen-progestin replacement is recommended unless contraindications exist 1

• Combined oral contraceptive pills may be more acceptable to younger women than traditional HRT 1
• Continue replacement until mean age of natural menopause 1
• Provides bone protection, cardiovascular benefits, and symptom relief
• Add calcium, vitamin D, weight-bearing exercise, smoking cessation for bone health 1

Important caveat: Oral estrogen increases corticosteroid-binding globulin, elevating total serum cortisol levels. This can confound assessment of adrenal reserve—interpret cortisol levels accordingly. 1

Postmenopausal Women

Diagnose central hypogonadism by absence of elevated FSH/LH. 1 Base estrogen replacement decisions after menopause on current general menopause guidelines rather than pituitary-specific recommendations. 1

Growth Hormone Replacement

Indications and Dosing

Offer GH replacement to patients with proven GH deficiency and no contraindications 1

• Starting dose:
  • Age <60 years: 0.2-0.4 mg/day
  • Age ≥60 years: 0.1-0.2 mg/day 1
• Women require higher doses, especially those on oral estrogen (due to GH resistance) 1
• Morbid obesity may require increased dosing 1

Monitoring Protocol

• Measure IGF-1 at 6 weeks after initiation, after dose changes, then every 6 months 1
• Maintain IGF-1 below upper limit of normal; reduce dose if side effects occur 1
• Monitor body weight, blood pressure, waist circumference, BMI every 6 months 1
• Assess bone mineral density by DXA every 18 months 1
• Check metabolic profile (glucose, lipids) every 6 months 1
• Periodically assess residual pituitary mass via MRI 1

Critical Timing Considerations

• Test HPA axis before AND after starting GH in patients not on glucocorticoid replacement, as GH can unmask adrenal insufficiency 1
• Treat central hypothyroidism before GH stimulation testing, as hypothyroidism impairs accurate GHD diagnosis 1

Benefits

GH replacement improves body composition (decreases visceral fat by 9% in women, increases lean mass by 7%), bone mineral density, lipoprotein metabolism, and quality of life. 1

Diabetes Insipidus Management (if present)

Postoperative DI Approach

• Use short-acting subcutaneous aqueous vasopressin initially for safer titration, as most postoperative DI resolves spontaneously 1
• Avoid scheduled DDAVP in first postoperative week due to risk of hyponatremia when transient DI resolves and risk of SIADH 7-10 days post-surgery 1
• Attempt DDAVP discontinuation weeks/months after surgery to assess posterior pituitary recovery 1

Long-term Management

• Individualize DDAVP schedules; some patients with partial DI prefer no treatment 1
• Patients must experience weekly polyuria phases (medication wearing off) to reduce hyponatremia risk 1
• Emergency bracelet/necklace recommended 1

Important interaction: Adrenal insufficiency can mask partial DI. Monitor for DI emergence after starting glucocorticoid replacement. Conversely, if DI improves unexpectedly, test for adrenal insufficiency. 1

Postoperative Reassessment Timeline

Retest all pituitary axes starting at 6 weeks after surgery, then periodically to monitor for development or resolution of deficiencies. 1 Recovery rates vary:

• Hypogonadotropic hypogonadism: Recovery is uncommon in men (8% in one study) but more frequent in women of reproductive age (63% regained regular cycles) 2
• Predictors of persistent HH: preoperative central hypothyroidism and male sex 2

Common Pitfalls to Avoid

1. Starting thyroid hormone before glucocorticoid replacement → adrenal crisis
2. Using fludrocortisone in secondary AI → unnecessary and potentially harmful
3. Over-replacing glucocorticoids → increased cardiovascular risk, osteoporosis, metabolic syndrome 1
4. Scheduled DDAVP in early postoperative period → hyponatremia
5. Ignoring oral estrogen effect on cortisol assays → misinterpretation of adrenal function
6. Starting GH without checking thyroid/adrenal function → unmasking deficiencies
7. Failing to educate about stress dosing → adrenal crisis during intercurrent illness